Assessment of Maternal and Fetal Serum Soluble Fms-like Tyrosine Kinase-1, Seromucoid, and Protein-bound Hexose in Women With Pre-eclampsia: A Case-control Study

Status: Completed
Location: See location...
Study Type: Observational
SUMMARY

The findings of markers of placental dysfunction in women with preeclampsia may suggest that these biomarkers may be useful tools for early detection of preeclampsia

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 45
View:

• Age group 18-45 years

• Gestational age of 26-41 weeks at the time of diagnosis for preeclampsia

• Delivered vaginally or abdominally

• Being of any parity (para 1 and more)

• Pregnancy being singleton or multiple pregnancies

• Willingness to provide informed consent

Locations
Other Locations
Iraq
Hawler Medical University
Erbil
Time Frame
Start Date: 2024-12-13
Completion Date: 2025-07-12
Participants
Target number of participants: 204
Treatments
Women with Preeclampsia
This group will comprise pregnant women having preeclampsia who are scheduled to undergo either vaginal or cesarean delivery. Their blood and their newborn blood will be collected and tested for a panel of inflammatory markers. This research aims to explore the potential association between maternal and neonatal inflammatory profiles and the development of preeclampsia, as well as its impact on pregnancy outcomes. By examining these markers, we hope to gain a better understanding of the underlying inflammatory mechanisms involved in preeclampsia.
Normotensive pregnant women
This group will consist of normotensive pregnant women during delivery who are scheduled to have their blood and their newborn blood tested for a panel of inflammatory markers and responses to inflammatory markers. One of the aims of this research is to investigate the potential association between maternal and neonatal inflammatory profiles in normotensive pregnancy in comparison to women with preeclampsia and their newborn By examining these markers
Related Therapeutic Areas
Sponsors
Leads: SHAHLA KAREEM ALALAF

This content was sourced from clinicaltrials.gov